← Browse by Condition
Medical Condition
metastatic colorectal cancer
Total Trials
12
Recruiting Now
12
Trial Phases
Phase 2, Phase 1, Phase 2
NCT06792695 Phase 2
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Enrollment
120 pts
Location
United States, Austr...
Sponsor
AstraZeneca
NCT06824064 Phase 2
Recruiting
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Enrollment
150 pts
Location
United States, Vietn...
Sponsor
Riboscience, LLC.
NCT06907342 Phase 2
Recruiting
Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)
Enrollment
148 pts
Location
Norway
Sponsor
St. Olavs Hospital
NCT07314294 Phase 2
Recruiting
Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients
Enrollment
54 pts
Location
China
Sponsor
Shanghai EpimAb Biotherapeutic...
NCT06242067 Phase 2
Recruiting
Second-line Treatment of Metastatic Colorectal Cancer
Enrollment
50 pts
Location
China
Sponsor
Qilu Hospital of Shandong Univ...
NCT06202001 Phase 1, Phase 2
Recruiting
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
Enrollment
70 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
NCT06776757 Phase 1, Phase 2
Recruiting
Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer
Enrollment
30 pts
Location
China
Sponsor
Cancer Hospital Chinese Academ...
NCT06149481 Phase 1, Phase 2
Recruiting
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Enrollment
60 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT07079631 Phase 1, Phase 2
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Enrollment
482 pts
Location
United States, Germa...
Sponsor
BioNTech SE
NCT06749015
Recruiting
A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Enrollment
100 pts
Location
China
Sponsor
Fudan University
NCT06493760 Phase 2
Recruiting
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Enrollment
130 pts
Location
China
Sponsor
Sunshine Guojian Pharmaceutica...
NCT06959550 Phase 2
Recruiting
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
Enrollment
90 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center